News
Cost of human life during COVID pandemic
Dr. Ariel Beresniak presents an analysis behind economic decisions being made amidst Covid-19, in this article for Causeur Magazine in May 2020. Link to the article Causeur Magazine - Le Coût de la Vie
Hydroxychloroquine in COVID: What is a “proof” ?
During unsettling Covid-19 times of emergency, Dr. Ariel Beresniak puts science back to its rightful place as a benchmark for decision-making, in this article published in Causeur magazine on 4th May 2020. Link to the article Causeur Magazine - Hydroxychloroquine contre le Covid-19: faut-il attendre une preuve?
Representative seroprevalence study: Interview of Dr Ariel Beresniak
Amid Covid-19 uncertainty, Dr. Ariel Beresniak was interviewed in this article by Corse Matin on Representative Seroprevalence Study. Link to the article Corse Matin - En Corse, quelles stratégies pour le déconfinement?
Test-and-treat strategy using Urea Breath Tests is cost-effective in managing symptoms and consequences from Helicobacter Pylori infection
Test-and-treat strategy using Urea Breath Tests is proven to be cost-effective in managing symptoms and consequences from Helicobacter pylori infection, thus contributing to preventing peptic ulcer and gastric cancer. For more information regarding this subject please refer to our Press Release.
USING UREA BREATH TESTS IS PROVEN TO BE A COST-EFFECTIVE METHOD FOR MANAGING SYMPTOMS AND CONSEQUENCES OF HELICOBACTER PYLORI BACTERIA INFECTION
Almost 60% of the world population is infected with the Helicobacter pylori bacteria: a new study establishes that a test-and-treat strategy using Urea Breath Tests is cost-effective in managing symptoms and consequences from this infection, thus contributing to prevent peptic ulcer and gastric cancer. Helicobacter pylori infection is a major public health issue affecting 60% of the world’s population with 90% of Peptic Ulcer attributed to and 80% of Gastric Cancers associated with Hp infection. With the support of an international expert panel composed of Pr Javier Gisbert & Dr Adrian Mc Nicholl (Spain), Pr Francesco Franceschi (Italy), Pr [...]
DMI presents the QALYs’ inadequacies during the Ethics Prize Seminar in Stockholm
Dr Ariel Beresniak took part in the Ethics Prize Seminar in Stockholm in October 2016, where he discussed once again how inadequate, inaccurate and unethical the QALY approach is when used for making a decision about new medicines' access to patients in need. This seminar was organised by the Swedish Council of Medical Ethics. The full seminar broadcast can be viewed here. Dr Ariel Beresniak's presentation starts at 1:50:13. More information on the QALYs and DMI's role in the ECHOUTCOME project: www.echoutcome.eu. Back to News